news

CUPERTINO, Calif., March 11 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that James Brown, President and Chief Executive Officer, will be presenting at the Cowen and Company 28th Annual Healthcare Conference on March 17, 2008 at 4:00 p.m. EST. The conference is being held at the Marriott Hotel in Boston. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) A live […]

CUPERTINO, Calif., Feb. 29 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that James Brown, President and Chief Executive Officer, will be presenting at the SIGnificant Investment Options in Healthcare conference hosted by Susquehanna Financial Group on Tuesday, March 4, 2008 at 2:45 p.m. EST. The conference is being held at the W Hotel, 541

CUPERTINO, Calif., Feb. 5 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2007. Total revenues were $6.6 million for the three months ended December 31, 2007, compared to $5.4 million for the same period in 2006. Net loss for the three months ended December

CUPERTINO, Calif., Feb. 4 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matthew J. Hogan, Chief Financial Officer, will be presenting at the BIO CEO and Investor Conference to be held at the Waldorf Astoria Hotel in New York on February 11, 2008 at 11:45 a.m. Eastern Time. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) A live audio webcast

CUPERTINO, Calif., Jan. 31 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) fourth quarter 2007 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Wednesday, February 6, 2008 at 9:00 a.m. EST (6:00 a.m. PST). When: Wednesday, February 6, 2008 at

CUPERTINO, Calif., Dec. 18 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today positive results from a Phase IIa clinical trial for ELADUR(TM), DURECT’s proprietary investigational transdermal pain patch. In this study of patients suffering from post-herpetic neuralgia, ELADUR showed improved pain control versus placebo during the 3-day continuous treatment period. In addition, ELADUR appeared well

CUPERTINO, Calif., Dec. 6 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that the pivotal Phase III trial for Remoxy had successfully met its primary endpoint (p<0.01) that was prospectively defined by the U.S. Food and Drug Administration (FDA) during the Special Protocol Assessment process. Remoxy, an investigational drug based on DURECT’s patented ORADUR(TM) technology,

CUPERTINO, Calif., Dec. 4 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview and update at two upcoming life sciences conferences in New York, NY. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) — NYSSA Biotech & Specialty Pharmaceuticals Industry Conference on Tuesday, December 11, 2007 at The New York Society of Security Analysts at

CUPERTINO, Calif., Nov. 20 /PRNewswire-FirstCall/ — via COMTEX — DURECT Corporation (Nasdaq: DRRX) announced today that it will present a corporate overview and update at the 19th Annual Piper Jaffray Health Care Conference on Tuesday, November 27, 2007 at 4:00 p.m. EST at The Pierre Hotel in New York. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) A live audio webcast

CUPERTINO, Calif., Nov. 1 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2007. Total revenues were $4.9 million for the three months ended September 30, 2007, compared to $5.1 million for the same period in 2006. Net loss for the three months ended September 30, 2007